VistaGen Therapeutics (VTGN) said Monday it has started enrollment for its phase 3 trial of its nasal spray fasedienol for the treatment of social anxiety disorder.
Fasedienol aims to provide an acute treatment option for social anxiety disorder by targeting nose-to-brain neurocircuitry, the company said.
Price: 3.10, Change: -0.05, Percent Change: -1.59
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments